Biotech Working on 'Functional Cure' for Type 1 Diabetes
MA Biotech Reports Positive Meeting with FDA
Research Report
Healthcare Tech Firm and Leading University to Join Forces
Mass. Biopharma Reports Positive Data and Announces New Program
Research Report
Pharma Co. Enrolls First Patient in Trial
Research Report
Florida Biotech Completes Enrollment in 'Pivotal' Drug Trial
Long Term Care Co.'s Target Price Raised
Research Report
AI Healthcare Co. Signs Partnership With Large Regional Health Plan
Research Report
Ontrak Inc. (NASDAQ: OTRK) announced it had signed a two-year strategic partnership with a large, northeast regional health plan focused on the plan's New York State members. This development comes as the company continues to rebuild its client base following a significant customer loss in Q1 2024, noted a Roth MKM research note. Promising Clinical Data and Strategic Partnerships Propel Oncology Co.
Elevation Oncology Inc.(ELEV:NASDAQ) reported its second-quarter 2024 financial results on August 6, highlighting significant progress in its clinical trials and ongoing business achievements. Read on to see why three experts believe this stock is a Buy.Boston Biotech Reports Promising Interim Data
Research Report
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note. AI Healthcare Co. Creates AI Pharmacy Assistant
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced it will roll out a new AI (artificial intelligence) Pharmacy Assistant to support pharmacists. One analyst says the company has positioned itself as a "central go-to resource."Analyst Says CA Pharma Underappreciated by Investors
Research Report
Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors. Analyst's Target Price for Biotech Massively Higher Than Current Price
Research Report
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price. Study Shows 93% Cough Suppression With Co.'s Drug
Clinical-stage pharmaceutical development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) announced the drug ifenprodil achieved a 93% reduction in median cough count in an acute guinea pig citric acid challenge study. Find out why one analyst says this stock is headed for a "major bull market."Could This Stock Be the Next Bellus Cough Treatment?
Contributed Opinion
Technical Analyst Clive Maund shares an extensive overview of Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA) to explain why he believes it is a Strong Buy. LA Biotech Unveils New Patented Nicotinamide Riboside Chloride
Research Report
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report. 
Streetwise Key Charts
